$HERB / LUFFF — they said Q3 would be the profitable quarter. Q3 just ended.
Herbal Dispatch (CSE: HERB / OTCQB: LUFFF) is still priced like a dead rec ticker. Q2 already showed the mix shift, they guided the next quarter to the inflection, and that quarter is now in the books.
What showed up in Q2:
* Gross profit up 74% to $0.75M even with lower overall revenue. They gave up top line on purpose.
* Gross margin 28.8% vs 15.7% in Q2 last year. First half also improved, 24.2% vs 20.0%.
* Medical more than doubled to $0.9M. YTD medical $1.5M vs $0.75M. Veteran channel at roughly a $2.2M annualized run rate. Insured, recurring, and management has previously pointed at 50%+ margins and about $6–7k annual spend per veteran patient.
* Exports +45% year over year to $0.7M. Q1 was a timing hole ($71k). Q2 is when the shipments landed.
* Exclusive EU-GMP processing deal in Portugal. That’s the pipe into Germany and the rest of regulated Europe without spending years certifying a Vancouver site.
* Net loss still about $0.7M, flat vs last year, but G&A included non-recurring IR spend tied to the Q4 financing. Strip that plus interest and non-cash and they called Q2 roughly break-even on an adjusted basis.
The call they already made:
On the Q2 release they guided positive quarterly adjusted EBITDA and operating cash flow on a consistent basis starting Q3 2026, if medical and export targets hold. Q3 closed September 30. The print is the next catalyst, not a story for next year. If they hit what they said, this stops being a turnaround narrative and becomes the first clean profitable quarter of the new mix.
Tape:
Canadian side is no longer dead. Average CSE volume has been sitting around 90k, and late September printed real days: about 250k on Sep 18, 189k on Sep 23, 359k on Sep 25. Several times a quiet session, on a name that used to trade in dribs and drabs. Still a 3-cent stock. Still illiquid. But the Canadian book is picking up into the quarter they said would be the inflection.
Why this can rerate:
Q4 2025 was the volume peak ($6.2M gross, $4.1M net, slightly positive Adj. EBITDA). H1 2026 is the mix quarter. Revenue is not beating that Q4 print and nobody should pretend it is. What is beating the old book is quality. Medical 2x. Exports back. Margin almost doubled year over year. House brands (Happy Hour BCLDB listings, Chomp, Northern Drip) instead of third-party consignment.
The bull case from here is simple. Veteran medical keeps compounding off a $2.2M run rate into a VAC reimbursed market that is still underpenetrated. Exports scale through the Portugal EU-GMP partner. Q3 prints the positive Adj. EBITDA and operating cash flow they just guided, and that quarter is already done. At a roughly $3–4M market cap, you are not paying for any of that. You are paying for the old rec story. If CSE volume keeps building, this doesn’t need a lot of dollars to move.
Risks stay in the post. Balance sheet as of Q1 was still payable-heavy (about $3.7M A/P), cash was thin, working capital was negative, and the going-concern language has not gone away. Guidance is not a result. Q3 has to show up in cash, not just margin. Germany is also getting stricter on late-stage GMP washing, which is why the Portugal partner matters more than a pack-room story.
Microcap, illiquid, but todays volume says otherwise can go to zero. But they told the market Q3 would be the profitable quarter, and that quarter just finished.